
|Articles|December 1, 2019
- Pharmaceutical Executive-12-01-2019
- Volume 39
- Issue 12
Pharmaceutical Executive, December 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive December 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Market Access: Employers as Barriers to Valueover 6 years ago
Lundbeck's Taj Bhardwaj: Market Access and Mental Healthover 6 years ago
The Route to Market Access in Europeover 6 years ago
A Multi-Stakeholder Perspective On Assessing Drug Valueover 6 years ago
When the Patient Loses in Market Accessover 6 years ago
Making Sense of Copay Accumulatorsover 6 years ago
Year in Review: R&D, Regulatory, and Reimbursement Hurdlesover 6 years ago
Who’s Going to Choose Where to Launch a Drug?over 6 years ago
Back to the Basics?over 6 years ago
Focus Report: Puerto RicoAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
The Risks and Benefits of FDA Reviewing Real-Time Data
3
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5




